These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 25088184

  • 1. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Kim CA, Spratlin JL, Armstrong DE, Ghosh S, Mulder KE.
    Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
    [Abstract] [Full Text] [Related]

  • 2. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [Abstract] [Full Text] [Related]

  • 3. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree JM, Mulder KE, Ghosh S, Spratlin JL.
    Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
    [Abstract] [Full Text] [Related]

  • 4. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H, Cassidy J.
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [Abstract] [Full Text] [Related]

  • 5. Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
    Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, Speers C, Cheung WY.
    Clin Colorectal Cancer; 2016 Jun; 15(2):179-85. PubMed ID: 26520019
    [Abstract] [Full Text] [Related]

  • 6. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
    Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A.
    Clin Colorectal Cancer; 2013 Dec; 12(4):275-9. PubMed ID: 24188686
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
    Prescrire Int; 2006 Jun; 15(83):109-1. PubMed ID: 16764102
    [Abstract] [Full Text] [Related]

  • 8. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C.
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract] [Full Text] [Related]

  • 9. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
    van Gils CW, Koopman M, Mol L, Redekop WK, Uyl-de Groot CA, Punt CJ.
    Acta Oncol; 2012 Jan; 51(1):57-64. PubMed ID: 22122695
    [Abstract] [Full Text] [Related]

  • 10. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [Abstract] [Full Text] [Related]

  • 11. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
    Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH.
    Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.
    Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A.
    Cancer; 2002 Apr 01; 94(7):1931-8. PubMed ID: 11932894
    [Abstract] [Full Text] [Related]

  • 13. Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
    Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, Bedenne L.
    Ann Surg Oncol; 2014 Aug 01; 21(8):2636-41. PubMed ID: 24639190
    [Abstract] [Full Text] [Related]

  • 14. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer.
    Demir L, Somali I, Oktay Tarhan M, Erten C, Ellidokuz H, Can A, Dirican A, Vedat Bayoglu I.
    J BUON; 2011 Aug 01; 16(4):682-8. PubMed ID: 22331722
    [Abstract] [Full Text] [Related]

  • 15. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
    Sastre J, Custodio A, Sanchez JC, Ortega L, Rodriguez L, Puente J, Corona J, Alfonso R, de las Heras M, Dıaz-Rubio E.
    Anticancer Drugs; 2011 Feb 01; 22(2):185-90. PubMed ID: 21218606
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR, Kim HC, Yun SH, Lee WY.
    Hepatogastroenterology; 2012 Feb 01; 59(120):2466-71. PubMed ID: 23169179
    [Abstract] [Full Text] [Related]

  • 17. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
    Kosugi C, Koda K, Ishibashi K, Yoshimatsu K, Tanaka S, Kato R, Kato H, Oya M, Narushima K, Mori M, Shuto K, Ishida H.
    Int J Colorectal Dis; 2018 Jun 01; 33(6):809-817. PubMed ID: 29484450
    [Abstract] [Full Text] [Related]

  • 18. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG.
    J Clin Oncol; 2007 Jan 01; 25(1):102-9. PubMed ID: 17194911
    [Abstract] [Full Text] [Related]

  • 19. PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.
    Aparicio T, Francois E, Cristol-Dalstein L, Carola E, Maillard E, Paillaud E, Retornaz F, Faroux R, André T, Bedenne L, Seitz JF.
    Dig Liver Dis; 2016 Feb 01; 48(2):206-7. PubMed ID: 26748426
    [No Abstract] [Full Text] [Related]

  • 20. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R, TOSCA (Three or Six Colon Adjuvant) Investigators.
    Ann Oncol; 2016 Nov 01; 27(11):2074-2081. PubMed ID: 27573560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.